A critical review of fosphenytoin sodium injection for the treatment of status epilepticus in adults and children
- PMID: 34726961
- DOI: 10.1080/14737175.2021.2001328
A critical review of fosphenytoin sodium injection for the treatment of status epilepticus in adults and children
Abstract
Introduction: Status epilepticus (SE) is a neurological emergency that can occur in patients with or without epilepsy. Rapid treatment is paramount to mitigate risks of neuronal injury, morbidity/mortality, and healthcare-cost burdens associated with SE. Fosphenytoin is the prodrug of phenytoin designed to enable faster administration and improved tolerability as compared to intravenous (IV) phenytoin in the treatment of SE.
Areas covered: This review evaluates the chemistry, pharmacokinetics, pharmacodynamics, safety, and tolerability of fosphenytoin. Efficacy data for fosphenytoin in the treatment of SE in adults and children are analyzed from initial phase I trials in 1988 through current phase III trials, including the Established Status Epilepticus Treatment Trial (ESETT).
Expert opinion: IV phenytoin is an established treatment of SE, but its alkaline aqueous vehicle is associated with dermatologic irritation and systemic complications when rapidly infused. The water-soluble nature of its prodrug, fosphenytoin, allows for rapid infusion, and it is rapidly converted to phenytoin when administered intravenously or intramuscularly. In the ESETT, IV fosphenytoin demonstrated similar efficacy in treatment of established SE when compared to IV levetiracetam and IV valproate in adults and children, making it a reasonable choice in the treatment of SE that is unresponsive to benzodiazepines.
Keywords: Status epilepticus; epilepsy; fosphenytoin; phenytoin; prodrug; seizure.
Similar articles
-
Efficacy of levetiracetam, fosphenytoin, and valproate for established status epilepticus by age group (ESETT): a double-blind, responsive-adaptive, randomised controlled trial.Lancet. 2020 Apr 11;395(10231):1217-1224. doi: 10.1016/S0140-6736(20)30611-5. Epub 2020 Mar 20. Lancet. 2020. PMID: 32203691 Free PMC article. Clinical Trial.
-
Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus.N Engl J Med. 2019 Nov 28;381(22):2103-2113. doi: 10.1056/NEJMoa1905795. N Engl J Med. 2019. PMID: 31774955 Free PMC article. Clinical Trial.
-
Levetiracetam versus fosphenytoin as a second-line treatment after diazepam for status epilepticus: study protocol for a multicenter non-inferiority designed randomized control trial.Trials. 2021 May 2;22(1):317. doi: 10.1186/s13063-021-05269-7. Trials. 2021. PMID: 33934714 Free PMC article.
-
Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs.Drug Saf. 2000 Jun;22(6):459-66. doi: 10.2165/00002018-200022060-00004. Drug Saf. 2000. PMID: 10877039 Review.
-
Clinical experience with fosphenytoin in adults: pharmacokinetics, safety, and efficacy.J Child Neurol. 1998 Oct;13 Suppl 1:S15-8; discussion S30-2. doi: 10.1177/0883073898013001051. J Child Neurol. 1998. PMID: 9796747 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical